All In Biotech

Free tool

FAERS Monitor: Udenyca

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761039 or its brand name (Udenyca, Pegfilgrastim-Cbqv). Reports on generic versions are filed under their own applications.

Reports

1,434

Serious

291

20% of reports

Hospitalization

125

Death reported

130

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device malfunction915
  • no adverse event715
  • product dose omission issue159
  • death99
  • accidental exposure to product39
  • device failure38
  • product label confusion36
  • neutrophil count decreased30
  • device leakage24
  • bone pain21
  • nausea20
  • white blood cell count decreased19
  • device issue17
  • product quality issue17
  • hospitalisation16

Reports by year received

View as table
YearReports
201978
2020119
202168
202255
202330
2024272
2025358
2026454

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,725 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device malfunctionSignal915193.5186.0173,323
product label confusionSignal3691.266.03,102
no adverse eventSignal71558.155.240,260
device failureSignal3836.726.81,282
neutrophil count decreasedSignal3010.87.6257
device leakageSignal248.15.5143
product dose omission issueSignal1597.96.9970
accidental exposure to productSignal395.64.1142
bone painSignal215.33.468
device issueSignal172.81.718
white blood cell count decreasedSignal192.61.617
product quality issue171.81.16
death991.71.428
hospitalisation161.50.92
nausea200.40.222

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.